IMMUNOBLUE, LLC
BETHESDA, MD
What changed
NIH R01 · $0.2M · Photothermal Nanoparticles Immune Engineer Tumor-specific T cells for Adoptive Cell Therapy
5mo agoGrant renewalJan 23, 2026Source filing (opens the source filing in a new tab)
Momentum
Momentum 40 out of 100, unchanged since the last recompute.
Some recent activity, at a steady rate.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Grant-only
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Grant
R42 · $1.1M · non-dilutive
Sep 3, 2024IMMUNOBLUE, LLC · PI SWEENEY, ELIZABETH E · NCI · award ends Aug 31, 2027 · Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles
NIH RePORTER · NIH RePORTER 11315832 (opens the source filing in a new tab)
- Grant
R01 · $237k · non-dilutive
Apr 3, 2024UNIV OF MARYLAND, COLLEGE PARK · PI FERNANDES, ROHAN · NCI · award ends Mar 31, 2029 · Photothermal Nanoparticles Immune Engineer Tumor-specific T cells for Adoptive Cell Therapy
NIH RePORTER · NIH RePORTER 11422341 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources